SYTL2 and osteosarcoma: Reportedly, miR-654-3p targets several genes associated with malignancy, such as P21 in gastric cancer (Deng et al., 2020), AKT3 in ovarian cancer (Duan et al., 2020), and SYTL2 in osteosarcoma (Zhou et al., 2020).